The therapy, known as isaralgagene civaparvovec, aims to replace the standard of care for Fabry patients, which currently relies on chronic enzyme replacement therapy. Clinical studies suggest the gene therapy enables long-term production of the alpha-galactosidase A enzyme, effectively reducing globotriaosylceramide buildup that causes multi-organ damage. Matthew B. Klein, CEO of PTC Therapeutics, stated the company intends to address the limitations of existing treatments by offering a single-dose alternative to the chronic regimen.

Fabry disease is a rare lysosomal disorder triggered by mutations in the GLA gene, leading to severe complications across the heart, kidneys, and nervous system. Isaralgagene civaparvovec has already secured Orphan Drug, Fast Track, and RMAT designations from the FDA, alongside PRIME eligibility from the European Medicines Agency. This acquisition marks a significant expansion of PTC's portfolio in rare disorder medicine as the firm prepares for the upcoming regulatory filing cycle.